Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q3 FY20 results · Oct–Dec 2019

Healthcare Global Enterprises reported revenue from operations of ₹277.93 crore (up 11.7% from Q3 FY19) and net loss of ₹29.16 crore for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	277.93	248.87	+11.7%	278.46	−0.2%
Other income	2.46	0.98	+151.0%	1.52	+61.8%
Total income	280.39	249.85	+12.2%	279.98	+0.1%
Profit before share of associates & JVs and tax	(25.62)	(4.95)	Loss widened	(22.02)	Loss widened
Share of profit/(loss) of associates & JVs	(2.22)	(2.28)		(4.89)
Net profit for the period	(29.16)	(6.03)	Loss widened	(25.26)	Loss widened
Attributable to shareholders of the company	(22.81)	(6.20)	Loss widened	(22.28)	Loss widened
EPS, basic (₹)	(2.57)	(0.71)	Loss widened	(2.51)	Loss widened
Net margin (%)	-10.5	-2.4		-9.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	172.98	159.67	+8.3%	173.71	−0.4%
Other income	3.13	1.24	+152.4%	2.36	+32.6%
Total income	176.11	160.91	+9.4%	176.07	+0.0%
Profit before tax	(7.54)	(0.35)	Loss widened	(5.02)	Loss widened
Net profit for the period	(4.27)	(0.18)	Loss widened	(3.47)	Loss widened
EPS, basic (₹)	(0.48)	(0.02)	Loss widened	(0.39)	Loss widened
Net margin (%)	-2.5	-0.1		-2.0

Consolidated

Filed with BSE: 14 Feb 2020, 14:48 IST
Board meeting: 12 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 14 Feb 2020, 14:48 IST
Board meeting: 12 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE